Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month
01 May 2023 - 9:00PM
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical
company developing and delivering novel therapies for the
management of central nervous system (CNS) disorders, is joining
Mental Health America (MHA) and the State of New York to raise
awareness of mental health during May is Mental Health Month.
In observance of the beginning of May is Mental
Health Month, Axsome’s new corporate headquarters, One World Trade
Center in New York City, will be lit in green, the color for mental
health awareness, on May 1, 2023. The lighting of One World Trade
Center in green was set in motion by the State of New York’s
Governor’s office, and complements MHA’s initiative to light up
more than 100 buildings and landmarks across the United States this
May to raise awareness for mental health and encourage the public
to learn more about their mental well-being and seek screening and
support.
According to recent data from the Substance
Abuse and Mental Health Services Administration (SAMHSA)1, an
estimated 14.7% of adolescents (5 million), aged 12-17, and 8.3% of
adults (21 million) in the past year had a major depressive
episode, characterized by at least one period of two weeks or
longer when for most of the day nearly every day, they felt
depressed or lost interest or pleasure in daily activities.
Further, more than 1 out of 8 adolescents (3.3 million) and almost
1 out of 20 adults (12.3 million) had serious thoughts about
suicide in the past year. These figures highlight the high
prevalence and serious impact of depression and other mental
illness on people in the United States, and the need for improved
access to treatment.
Axsome is supporting this year’s MHA ‘look
around, look within’ campaign in observance of May is Mental Health
Month. This campaign aims to help people realize how much our
overall health is affected by our environment and that mental
health can be improved by making where we live a healthier and
safer place. Axsome is proud to stand in solidarity with MHA and
other national organizations that provide mental health resources
to those in need. To learn about these organizations and the
resources they provide, please visit the following websites:
- Anxiety
and Depression Association of
America (ADAA) (https://adaa.org).
ADAA’s mission focuses on improving quality of life for those with
anxiety, depression, OCD, PTSD, and co-occurring disorders through
education, practice, and research.
- The
Depression and Bipolar Support
Alliance (DBSA) (https://www.dbsalliance.org).
DBSA is a leading national peer-focused mental health organization,
whose mission is to provide hope, help, support, and education for
individuals who live with mood disorders.
- Mental
Health America
(MHA) (https://www.mhanational.org).
MHA's work is driven by its commitment to promote mental health as
a critical part of overall wellness, including prevention services
for all; early identification and intervention for those at risk;
and integrated care, services, and support for those who need them,
with recovery as the goal. Resources provided by the MHA include a
free online mental health screen, which can be found
at MHAscreening.org, to help identify signs
of mental health problems.
-
National Alliance on Mental Illness (NAMI)
(https://www.nami.org/). NAMI is the nation’s
largest grassroots mental health organization dedicated to building
better lives for the millions of Americans affected by mental
illness.
If you or someone you know is in crisis, the
988 Suicide & Crisis Lifeline
(https://988lifeline.org/) is a free confidential
support service available 24 hours a day, 7 days a week across the
United States. When people call, text, or chat 988, they will be
connected to trained counselors that are part of the existing
Lifeline network. These trained counselors will listen, understand
how their problems are affecting them, provide support, and connect
them to resources if necessary.
About Axsome Therapeutics,
Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical
company developing and delivering novel therapies for central
nervous system (CNS) conditions that have limited treatment
options. Through development of therapeutic options with novel
mechanisms of action, we are transforming the approach to treating
CNS conditions. At Axsome, we are committed to developing products
that meaningfully improve the lives of patients and provide new
therapeutic options for physicians. For more information, please
visit the Company’s website at axsome.com. The Company may
occasionally disseminate material, nonpublic information on the
company website.
Forward Looking Statements
Certain matters discussed in this press release
are “forward-looking statements”. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. In particular, the Company’s statements
regarding trends and potential future results are examples of such
forward-looking statements. The forward-looking statements include
risks and uncertainties, including, but not limited to, the
continued commercial success of our Sunosi® and Auvelity® products
and the success of our efforts to obtain any additional
indication(s) with respect to solriamfetol and/or AXS-05; the
success, timing and cost of our ongoing clinical trials and
anticipated clinical trials for our current product candidates,
including statements regarding the timing of initiation, pace of
enrollment and completion of the trials (including our ability to
fully fund our disclosed clinical trials, which assumes no material
changes to our currently projected expenses), futility analyses and
receipt of interim results, which are not necessarily indicative of
the final results of our ongoing clinical trials, and the number or
type of studies or nature of results necessary to support the
filing of a new drug application (“NDA”) for any of our current
product candidates; our ability to fund additional clinical trials
to continue the advancement of our product candidates; the timing
of and our ability to obtain and maintain U.S. Food and Drug
Administration (“FDA”) or other regulatory authority approval of,
or other action with respect to, our product candidates; whether
issues identified by FDA in the complete response letter may impact
the potential approvability of the Company’s NDA for AXS-07 for the
acute treatment of migraine in adults with or without aura,
pursuant to our special protocol assessment for the MOMENTUM
clinical trial; the Company’s ability to successfully defend its
intellectual property or obtain the necessary licenses at a cost
acceptable to the Company, if at all; the successful implementation
of the Company’s research and development programs and
collaborations; the success of the Company’s license agreements;
the acceptance by the market of the Company’s products and product
candidates, if approved; the Company’s anticipated capital
requirements, including the amount of capital required for the
continued commercialization of Sunosi and Auvelity and for the
Company’s commercial launch of its other product candidates, and
the potential impact on the Company’s anticipated cash runway;
unforeseen circumstances or other disruptions to normal business
operations arising from or related to COVID-19; and other factors,
including general economic conditions and regulatory developments,
not within the Company’s control. The factors discussed herein
could cause actual results and developments to be materially
different from those expressed in or implied by such statements.
The forward-looking statements are made only as of the date of this
press release and the Company undertakes no obligation to publicly
update such forward-looking statements to reflect subsequent events
or circumstance.
Axsome Contacts: Investors:Mark JacobsonChief
Operating OfficerAxsome Therapeutics, Inc.One World Trade Center,
22nd FloorNew York, NY 10007Tel:
212-332-3243Email: mjacobson@axsome.comwww.axsome.com
Media:Darren OplandDirector, Corporate Communications Axsome
Therapeutics, Inc.One World Trade Center, 22nd FloorNew York, NY
10007Tel: 929-837-1065Email: dopland@axsome.comwww.axsome.com
References:
- Substance Abuse
and Mental Health Services Administration. (2022). Key substance
use and mental health indicators in the United States: Results from
the 2021 National Survey on Drug Use and Health (HHS Publication
No. PEP22-07-01-005, NSDUH Series H-57). Rockville, MD: Center for
Behavioral Health Statistics and Quality, Substance Abuse and
Mental Health Services Administration. Retrieved from
https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report.
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From Apr 2023 to Apr 2024